Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Verve Therapeutics + Eli Lilly

closed

$VERV acquired by Eli Lilly for $1.3B

Deal Summary

Deal Value
$1.3B
Price/Share
$10.5
Announced
Jun 17, 2025
Closed
Jul 25, 2025

Fund Positioning

5 of 20 tracked specialist biotech funds held $VERV — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Casdin Capital4.1M$46.0MMar 2025Yes
BVF Partners6.9M$31.6MMar 2025Yes
Baker Bros. Advisors1.7M$19.0MMar 2025Yes
Redmile Group740K$8.3MMar 2025Yes
EcoR1 Capital1.3M$5.7MMar 2025Yes
← All biotech acquisitions